Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01922843 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
A Phase 2 study, sponsored by Deltanoid Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT01922843 is a Phase 2 study that has completed, run by Deltanoid Pharmaceuticals. The registered enrollment target is 62 participants.
The verdict
NCT01922843, a Phase 2 study, has completed, sponsored by Deltanoid Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
The goal of this study is to test a new vitamin D compound for its ability to reduce parathyroid hormone levels in patients who are on hemodialysis.
Interventions
- DRUG Placebo
- DRUG DP001 softgel capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01922843
The ClinicalTrials.gov registry entry for NCT01922843 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Deltanoid Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01922843 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01922843 about?
NCT01922843 is a clinical study titled "A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis". The goal of this study is to test a new vitamin D compound for its ability to reduce parathyroid hormone levels in patients who are on hemodialysis.
What is the current status of trial NCT01922843?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2013-09. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01922843?
The interventions under investigation include: Placebo (DRUG), DP001 softgel capsules (DRUG).
Who is sponsoring clinical trial NCT01922843?
This trial is sponsored by Deltanoid Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.